Antimicrobial Resistance & Infection Control

Table 4 Comparison of mean logs ratios of the different macrolide–resistant genes before, during and after treatment

From: Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin

		Placebo		Azithromycin
		Mean*	SD	Mean	SD	P value**
mefA	M6	−0.22 (n = 27)	1.00	0.51 (n = 34)	0.47	0.0001
mefA	M12	−0.39 (n = 26)	1.21	0.33 (n = 30)	0.68	0.002
ermF	M6	−0.14 (n = 11)	1.35	0.86 (n = 18)	0.99	0.0687
	M12	0.15 (n = 12)	0.94	1.04 (n = 17)	0.80	0.0124
ermB	M6	−0.32 (n = 20)	1.48	0.69 (n = 33)	0.93	0.0116
	M12	−0.42 (n = 18)	1.33	0.89 (n = 30)	1.05	0.0013

^*mean of the log gene abundance ratio compared to baseline
**p values for comparison of mean abundance at either 6 or 12 months and baseline, by Wilcoxon ranked sum test

Back to article page

ISSN: 2047-2994

Contact us

General enquiries: journalsubmissions@springernature.com